Teva (NYSE:TEVA) Stages Fierce Blockbuster Drug Competition To Zydus Cadila


The stock of Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) closed at $17.09 gaining 0.29% in yesterday’s trading session. The blockbuster generic drug from Cadila Healthcare which has been trusted in the treatment of ulcerative colitis for a long time is currently facing stiff competition from Teva Pharmaceutical Industries.

It was early this week when Teva took to the unveiling of the generic version of Irish firm Shire’s Lialda. Several analysts have made their projections and the one thing they all seem to agree upon is the fact that any time soon the margins of the drug might be shrinking as completion escalates in the US market. The other probable fillers apart from Teva will be Amneal and Mylan NV (NASDAQ:MYL) who if all moves according to plan might be unveiling their respective products in 2018-19.

An analyst working with Edelweiss Securities Deepak Malik spoke in relation to the coming of new products into the market. According to him, that could end up making the drug loose quite much in terms of its overall attractiveness. It might end up being rated just like any other drug in the market.

After their assessments, analysts have made a joint statement outlining that the drug, which happens to be a generic of mesalamine will most probably be associated with $1.5 billion in terms of the market size.

Zydus Cadila, which happens to be the other name for Cadila Healthcare is said to have been at the frontline in making the filing for the new drug application in the US which would be serving as the generic version of Lialda.

It was in the previous year that it was reported that Zydus was busy in its Moraiya facility near Ahmedabad where it unveiled its generic version of Lialda. To be more specific, that was around mid-July and along the same line it is worth mentioning that the drug has significantly contributed to the growth of this company in the US a huge deal this fiscal.

An official well conversant with the most recent developments has outlined that the generic has turned out to be a monumental launch for Cadila this particular year and it is expected to fetch high revenues for the company in time to come.


Please enter your comment!
Please enter your name here